Berlin, Germany-based ProBioGen is a contract development and manufacturing organization (CDMO) focusing on production of therapeutic antibodies and glycoproteins.
The service provider announced that it has signed an agreement with Immunogenesis, under which it will manufacture the latter company’s monoclonal antibody lead candidate, a potential treatment with an immuno-oncology indication.
A spin-off of University of Texas, Immunogenesis will utilize ProBioGen’s Chinese hamster ovary (CHO)-based expression platform, known as CHO.RIGHT, that enables high-titer cell line development.
The partnership will see ProBioGen conduct cell line development, process development and good manufacturing practice (GMP) manufacturing work in 1,000L bioreactor scale, in order to cover the clinical supply needs for Immunogenesis’ project.
Immunogenesis holds a pipeline focusing on achieving effective immunity against non-inflamed tumors, known as ‘cold’ tumors.
This means that the developer looks to generate sufficient anti-tumor T cells; subsequently protect and expand these cells inside the tumor; and ultimately achieve reduction in hostile tumor metabolism.
Commenting on the partnership with ProBioGen, Michael Curran, founder of Immunogenesis, stated that the CDMO forms the right partner as it holds the required scientific expertise and the ‘can-do’ mindset to assist in the realization of Immunogenesis’ scientific project.
Financial terms of the partnership were not disclosed.
